All In Biotech

Drug Trial Radar · NCT00562315

FACBC PET/CT for Recurrent Prostate Cancer

18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma (CA129356-01).

Last checked: Nov 20, 2026Latest source record: Jun 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

128

Actual

Start

Oct 2007

Primary completion

Jul 2015

Study completion Jul 2015

Sponsor

Lead sponsor
David M. Schuster, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Nov 22, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
Single (investigator)
Primary purpose
Diagnostic
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hypothesis:Anti-\[18F\]FACBC PET-CT will adequately detect local and extraprostatic recurrence, and lead to better characterization of disease status in restaging patients. This is a study that will test a compound (chemical substance) that has a small amount of radioactivity attached to it. This substance has a natural tendency to go to prostate tissue. The substance is called \[18\]FACBC and it is given in the form of an injection into a vein. After the substance reaches the prostate, scans called PET or Positron Emission Tomography, are done. This is similar to having CAT scans or x-rays. Usually a compound called \[18\]FDG is used for PET scans but this substance is eliminated by the kidneys and cannot reach the prostate. This substance called \[18\]FACBC is not eliminated by the kidneys and may allow tumors in the prostate to be seen better. It is sometimes difficult to tell if a growth on the prostate is cancer with scans or x-rays that are usually done. Anti-\[18F\]FACBC PET-CT will be compared to ProstaScint (In-capromab pendetide) which is the conventional imaging for prostate cancer. Investigators will be blinded of the intervention. This study will look at how the \[18\]FACBC goes into the prostate tissue and determine its ability to detect recurrent prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • FACBCDrug

    Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan

  • ProstaScinctOther

    ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With True Positive Scans Within the Prostate BedTime frame: Up to 5 years
  2. Number of Participants With False Positive Scans Within the Prostate BedTime frame: Up to 5 years
  3. Number of Participants With True Negative Scans Within the Prostate BedTime frame: Up to 5 years
  4. Number of Participants With False Negative Scans Within the Prostate BedTime frame: Up to 5 years
  5. Number of Participants With True Positive Scans Outside the Prostate BedTime frame: Up to 5 years
  6. Number of Participants With True Negative Scans Outside the Prostate BedTime frame: Up to 5 years
  7. Number of Participants With False Positive Scans Outside the Prostate BedTime frame: Up to 5 years
  8. Number of Participants With False Negative Scans Outside the Prostate BedTime frame: Up to 5 years
  9. Diagnostic Performance of Anti-[18F]FACBC PET-CT Imaging in Detection of Extra-prostatic Recurrence of Prostate CarcinomaTime frame: Up to 5 years
  10. Diagnostic Performance of Anti-[18F]FACBC PET-CT Imaging in Detection of Recurrent Prostate Carcinoma in the Prostate BedTime frame: Up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emory University Hospital

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.